244 related articles for article (PubMed ID: 27771290)
41. Myelodysplastic syndrome hematopoietic stem cell.
Li J
Int J Cancer; 2013 Aug; 133(3):525-33. PubMed ID: 23047726
[TBL] [Abstract][Full Text] [Related]
42. How recent advances in high-risk myelodysplastic syndrome physiopathology may impact future treatments.
Cluzeau T; Robert G; Jacquel A; Auberger P
Curr Pharm Des; 2013; 19(30):5362-73. PubMed ID: 23394086
[TBL] [Abstract][Full Text] [Related]
43. [Recent advances in the treatment of myelodysplastic syndromes].
Gelsi-Boyer V; Vey N
Rev Med Interne; 2006 Aug; 27(8):600-9. PubMed ID: 16713027
[TBL] [Abstract][Full Text] [Related]
44. When is the optimal timing for allogeneic transplantation in the case of MDS patients treated with hypomethylating agents?
Sohn SK; Moon JH
Expert Rev Hematol; 2013 Aug; 6(4):389-95. PubMed ID: 23991925
[TBL] [Abstract][Full Text] [Related]
45. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
46. [Treatment for myelodysplastic syndrome: with a focus on the low-risk group].
Gotoh A
Rinsho Ketsueki; 2017; 58(10):1951-1959. PubMed ID: 28978837
[TBL] [Abstract][Full Text] [Related]
47. Optimal sequencing of treatments for patients with myelodysplastic syndromes.
Itzykson R; Fenaux P
Curr Opin Hematol; 2009 Mar; 16(2):77-83. PubMed ID: 19468268
[TBL] [Abstract][Full Text] [Related]
48. Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome.
Kennedy JA; Ebert BL
J Clin Oncol; 2017 Mar; 35(9):968-974. PubMed ID: 28297619
[TBL] [Abstract][Full Text] [Related]
49. The evolution of hematopoietic SCT in myelodysplastic syndrome.
Kindwall-Keller T; Isola LM
Bone Marrow Transplant; 2009 Apr; 43(8):597-609. PubMed ID: 19252532
[TBL] [Abstract][Full Text] [Related]
50. The role of hematopoietic stem cell transplantation in myelodysplastic syndrome.
Thompson JE; Luger SM
Oncology (Williston Park); 2005 Apr; 19(4):533-42; discussion 542-4, 547-8. PubMed ID: 15934520
[TBL] [Abstract][Full Text] [Related]
51. Uncoding the genetic heterogeneity of myelodysplastic syndrome.
Lindsley RC
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):447-452. PubMed ID: 29222292
[TBL] [Abstract][Full Text] [Related]
52. Myelodysplastic Syndromes: A New Decade.
Volpe VO; Garcia-Manero G; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2022 Jan; 22(1):1-16. PubMed ID: 34544674
[TBL] [Abstract][Full Text] [Related]
53. Treatment-related myelodysplastic syndrome: molecular characteristics and therapy.
Bhatia R; Deeg HJ
Curr Opin Hematol; 2011 Mar; 18(2):77-82. PubMed ID: 21252656
[TBL] [Abstract][Full Text] [Related]
54. Implications of molecular genetic diversity in myelodysplastic syndromes.
Bejar R
Curr Opin Hematol; 2017 Mar; 24(2):73-78. PubMed ID: 27875374
[TBL] [Abstract][Full Text] [Related]
55. New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities.
Abou Zahr A; Bernabe Ramirez C; Wozney J; Prebet T; Zeidan AM
Expert Rev Hematol; 2016; 9(4):377-88. PubMed ID: 26734762
[TBL] [Abstract][Full Text] [Related]
56. Evolving strategies in the treatment of MDS and AML.
Stone R; Sekeres M; Garcia-Manero G
Clin Adv Hematol Oncol; 2009 Aug; 7(8):1-14; quiz 2 p following 14. PubMed ID: 19927982
[TBL] [Abstract][Full Text] [Related]
57. Myelodysplastic syndromes: Biological and therapeutic consequences of the evolving molecular aberrations landscape.
Schwind S; Jentzsch M; Kubasch AS; Metzeler KH; Platzbecker U
Neoplasia; 2021 Nov; 23(11):1101-1109. PubMed ID: 34601234
[TBL] [Abstract][Full Text] [Related]
58. [MDS: Recent progress in molecular pathogenesis and clinical aspects].
Harada H
Rinsho Ketsueki; 2017; 58(10):1941-1950. PubMed ID: 28978836
[TBL] [Abstract][Full Text] [Related]
59. [Myelodysplastic syndromes].
Thol F; Heuser M; Ganser A
Internist (Berl); 2015 Apr; 56(4):364-73. PubMed ID: 25700647
[TBL] [Abstract][Full Text] [Related]
60. Genetic and molecular characterization of myelodysplastic syndromes and related myeloid neoplasms.
Patel B; Hirsch C; Clemente M; Sekeres M; Makishima H; Maciejewski JP
Int J Hematol; 2015 Mar; 101(3):213-8. PubMed ID: 25690487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
